OPR - Delayed Quote USD

XFOR Jan 2025 1.500 call (XFOR250117C00001500)

0.3500

-0.1500

(-30.00%)

At close: April 26 at 10:52 AM EDT

Key Events

Loading Chart for XFOR250117C00001500

9/21 12:03 PM

DELL

Previous Close 0.5000
Open 0.4500
Bid 0.3000
Ask 0.5000
Strike 1.50
Expire Date 2025-01-17
Day's Range 0.3500 - 0.4500
Contract Range --
Volume 2
Open Interest 269

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…

XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript

Q4 2023 X4 Pharmaceuticals Inc Earnings Call

X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

XFOR: Update on Phase 2 CN Trial at ASH 2023

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

XFOR: Mavorixafor NDA Accepted by FDA; PDUFA Date of April 30, 2024

XFOR: Mavorixafor NDA Accepted by FDA; PDUFA Date of April 30, 2024